(19)
(11) EP 3 576 719 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.07.2022 Bulletin 2022/28

(45) Mention of the grant of the patent:
07.07.2021 Bulletin 2021/27

(21) Application number: 18706085.0

(22) Date of filing: 06.02.2018
(51) International Patent Classification (IPC): 
A61K 9/48(2006.01)
A61K 31/137(2006.01)
A61K 47/36(2006.01)
 A61K 9/00(2006.01)
A61K 47/10(2017.01)
A61P 25/36(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0053; A61K 47/10; A61K 47/36; A61K 9/4866; A61K 31/137; A61P 25/36
(86) International application number:
PCT/US2018/017019
(87) International publication number:
WO 2018/145071 (09.08.2018 Gazette 2018/32)

(54)

ABUSE DETERRENT FORMULATIONS OF AMPHETAMINE

MISSBRAUCHSVERHINDERNDE FORMULIERUNGEN VON AMPHETAMIN

FORMULATIONS ANTI-ABUS D'AMPHÉTAMINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.05.2017 US 201715591677
06.02.2017 US 201762455227 P

(43) Date of publication of application:
11.12.2019 Bulletin 2019/50

(60) Divisional application:
21183311.6 / 3943066

(73) Proprietor: Vallon Pharmaceuticals, Inc.
Philadelphia, PA 19103 (US)

(72) Inventors:
  • BAKER, David
    Philadelphia, PA 19103 (US)
  • DANIELY, Yaron
    Philadelphia, PA 19103 (US)
  • RON, Hanna
    Philadelphia, PA 19103 (US)
  • SINER, David
    Philadelphia, PA 19103 (US)

(74) Representative: Cooley (UK) LLP 
22 Bishopsgate
London EC2N 4BQ
London EC2N 4BQ (GB)


(56) References cited: : 
WO-A1-2014/190440
 US-A1- 2016 317 530
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).